In this Axios column, Drew Altman shows that unlike the individual market, narrow networks are not common in the much larger group market, and discusses why and why it matters.
- view as grid
- view as list
In this Axios column, Drew Altman analyzes recent unemployment numbers for older workers and discusses how millions of uninsured older workers could lead to a greater push for incremental Medicare expansion proposals.
In his Axios column, Drew Altman discusses new data on the surge of new infections in long-term care facilities in COVID-19 hotspots. The dominant narrative about the Sunbelt surge in new cases is that the infected population is younger, but he says that’s not the whole story. There is also a spike in cases in long-term care facilities, especially in Florida and Texas.
In this Axios column, Drew Altman looks at how the heroic performance of the nation’s doctors on the frontlines of coronavirus care and effective communication by many physician scientists on television, is shifting the public’s views, with twice as many Americans now saying doctors put people ahead of profits than they did in earlier KFF polling.
In this column, Drew Altman zeroes in on a key test for when the implementing rules are written for the new executive order on hospital price transparency: consumers will need to know what amount they must pay out of pocket to really help them shop on price.
Sweden’s Coronavirus Strategy Should Not Be the World’s — But Aspects of It Are Worthy of Consideration
In an article for Foreign Affairs, KFF’s Josh Michaud discusses Sweden’s response to novel coronavirus.
As state and local governments ease social distancing orders, many employers and workers face decisions about a physical return to the workplace. Drew Altman’s latest Axios column analyzes the numbers and finds that, “An estimated 25-30 million people are caught in the middle of the coronavirus economy — they’re unable to work from home but also face a high risk of severe infection.”
Drew Altman’s column in Axios: the U.S. now spends twice per capita what other wealthy countries do on health care. But while drug costs get all the time in public debate, it’s hospital and outpatient spending that mostly explains the difference. And that will be impossible to take on without real pain and political risk, he says.
Drew Altman’s Axios column draws on data from the new KFF COVID-19 Vaccine Monitor to assess where the country stands on vaccine hesitancy.
New analysis from Drew Altman in his latest Axios column on the impact of the coronavirus pandemic on national health spending.